In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH). The company’s shares opened today at $125.45, close to its 52-week high of $129.34.
According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -3.8% and a 52.1% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Motus Gi Holdings Inc, and Integra Lifesciences.
Zimmer Biomet Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $138.33, implying a 10.3% upside from current levels. In a report issued on August 13, Needham also maintained a Buy rating on the stock with a $150 price target.
.
See today’s analyst top recommended stocks >>
Zimmer Biomet Holdings’ market cap is currently $25.51B and has a P/E ratio of 14.95. The company has a Price to Book ratio of 2.12.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Tony Collins, the VP, Contr & CAO of ZBH sold 2,778 shares for a total of $349,359.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products, sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. The company operates through three geographical segments: America, Europe and Asia Pacific.
